Floatz logo

Efavirenz

Alzheimer Disease, Early Onset

Case Western Reserve UniversitySmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Alzheimer Disease, Early Onset cohort.

Asset / SponsorPhaseRating
RG6289
Banner Health
Phase 2/3B
Donanemab
Banner Health
Phase 2/3B
Gonadotropin-Releasing Hormone
Nelly Pitteloud
Phase 2/3CCC
Gnrh
Nelly Pitteloud
Phase 2/3CCC
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION
Nelly Pitteloud
Phase 2/3CCC

View all 26 →

Same molecule, other indications

Efavirenz is also rated in:

lipodystrophyDormant
A
Indicative ·
82 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
77 / 100
View asset →
lipodystrophyDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →